Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 2/20 | 0.61 |
| ▸ | HTR2A | P28223 | 9/20 | 0.55 |
| ▸ | HTR2C | P28335 | 8/20 | 0.55 |
| ▸ | CNR1 | P21554 | 1/20 | 0.53 |
| ▸ | DRD2 | P14416 | 5/20 | 0.51 |
| ▸ | MAPT | P10636 | 4/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4875370 | 0.93 | HTR6 (0.70) | HTR6HTR2AHTR2CCNR1DRD2 | |
| Hydrochloric Acid SCHEMBL5130227 | 0.91 | HTR6 (0.68) | HTR6HTR2AHTR2CCNR1DRD2 | |
| SCHEMBL14074161 | 0.90 | HTR2A (0.63) | HTR6HTR2AHTR2CCNR1DRD2 | |
| SCHEMBL22221974 | 0.89 | HTR6 (0.55) | HTR6HTR2AHTR2CCNR1DRD2 | |
| Cyanide SCHEMBL28580911 | 0.88 | HTR6 (0.65) | HTR6HTR2AHTR2CCNR1DRD2 | |
| SCHEMBL7613059 | 0.86 | KDM4E (0.64) | HTR6HTR2AHTR2CMAPTKDM4E | |
| SCHEMBL7995810 | 0.82 | GNRHR (0.54) | — | |
| SCHEMBL2789743 | 0.80 | HTR6 (0.71) | HTR6HTR2AHTR2CCNR1DRD2 | |
| SCHEMBL7997254 | 0.80 | HTR6 (0.53) | HTR6MAPTKDM4EKMT2A | |
| SCHEMBL6476562 | 0.79 | HTR6 (0.55) | HTR6HTR2AHTR2CCNR1DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200223826-A1 | Glucose-6-Phosphate Dehydrogenase (G6PD)-Modulating Agents And Methods Of Treating G6PD Deficiency | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2020-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200223826-A1 | Glucose-6-Phosphate Dehydrogenase (G6PD)-Modulating Agents And Methods Of Treating G6PD Deficiency | G6PD, DPYD, G6PC1 | HTR6 2080/4885HTR2A 2419/4885HTR2C 3437/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.